📊 MAG7 vs. S&P 493 – April 7 → August 12, 2025 The market picture is clear: The big ones are carrying, the broad base is providing limited support. Here's an X-ray of the last 4.5 months ⬇️ 🔹 MAG7 (AAPL, AMZN, GOOGL, META, MSFT, NVDA, TSLA) • Index Weight: ~35.4% 📈 (record high) • Performance: +10.7% • Earnings growth +28% in Q1, continued strong in Q2 • Still priced in with the "AI + quality growth" narrative • Risk: High valuation → susceptibility to surprises 🔹 S&P 493 (Remainder) • Performance: +4.1% (RSP index) • Breadth: 55% at 200-day moving average • Earnings growth, but above-index momentum is limited • Valuation is more reasonable → potential for "catch-up" 🔹 Overall Index (S&P 500) • Performance: +8.3% • P/E: 22.1x → Above 5- and 10-year moving averages • Q2 earnings growth: 11.8% (mega-caps again the driving force) 📌 Reading: While the MAG7 rebounded ~35% from its April 7 lows, the broad base remains moderate. Most of the index's rise comes from giants. Concentration risk is high → the impact is disproportionate, both in the uptrend and downtrend. 📌 Tactical Recommendation: - Strengthen the Majors: Include companies with growing profits and strong balance sheets (excess cash) within the MAG7 in your main portfolio. - Layer the Rest: Add small-medium weightings to sectors (healthcare, select industrials, some defensive stocks) within the 493 whose earnings expectations have been revised upwards and whose prices remain reasonable. - Divide Risk: Don't concentrate your investment solely on giant stocks; Diversify with products like the equal-weight index (RSP) or the S&P 500 – Excluding Top 10 Stocks. - Follow the Macro: Fed interest rate decisions, inflation data, and global trade news can quickly change the direction of mega-cap stocks in particular. This is not investment advice, but for informational purposes only!!! #MAG7 #SP500 #Finance #StockMarket #Investment #Stocks #MarketAnalysis #Investor #BorsaIstanbul #NASDAQ #WallStreet #Economy #FinancialLiteracy #Index #InvestmentStrategy #Portfolio

As the rally in technology stocks boosts market sentiment, investors continue to assess the impact of Trump's new tariffs. 🔹 S&P 500 futures: +0.3% 🔹 Nasdaq 100 futures: +0.3% 🔹 Dow futures: +0.2% 📊 Bond Market 10Y return: 4.26% (flat) 2Y return: +1bp ➡ 3.75% 📌 Thursday Summary S&P 500: -0.08% (Eli Lilly earnings pressured) Nasdaq: +0.35% 🆙 Mag-7: +0.40% 📈 (All-time high) 💬 Deutsche Bank – Jim Reid: “Trump’s chip tax exemptions and the easing of Russia-Ukraine tensions have tempered optimism. Tariffs have taken effect, but the market reaction has been weak.” 📰 Other Developments Trump tariffs officially began last night Fed Governor Waller is emerging as a candidate for chairman after Powell Today's data agenda is quiet; St. Louis Fed President Musalem will speak #SP500 #Nasdaq #DowJones #TrumpTariffs #BondMarket #Fed #Markets

$HIMS Hims & Hers' Weight Loss Strategy Shakes Up Balance Sheet Metrics! 📉 Telehealth platform Hims & Hers surprised investors by missing Wall Street expectations for the first time, despite a 73% year-over-year increase in revenue to $544.8 million in the second quarter. This led to a 13% post-session drop in the stock. The primary reason behind this unexpected decline in figures is forced changes to the company's GLP-1 (weight loss) drug strategy. With the FDA's end of the semaglutide shortage, Hims was forced to change its sales model for more affordable generic GLP-1 drugs. This led to a decline in online GLP-1 revenue from $230 million in the first quarter to $190 million in the second quarter, and a decrease in average revenue per subscriber from $84 to $74. While the company achieved 31% year-over-year subscriber growth, reaching 2.4 million subscribers, uncertainties surrounding its GLP-1 strategy and developments such as the termination of its partnership with Novo Nordisk cast doubt on its growth narrative. Negative free cash flow is another concern. Hims & Hers will now attempt to navigate this challenging period by focusing on personalized GLP-1 therapies.

📊 $LLY | Eli Lilly Q2'25 Financial Results Strong Growth, Deepening Pipeline 🔹 Revenue: $15.56B (+38% YoY) 🟢 🔹 Adjusted EPS: $6.31 (+61% YoY) 🟢 🔹 Zepbound: $3.38B (+172%) 🔹 Mounjaro: $5.20B (+68%) 💡 Zepbound and Mounjaro solidify Eli Lilly's leadership in the metabolic diseases segment, with this quarter's results demonstrating momentum for both prescription penetration and patient acceptance of these products. 📌 FY25 guidance revised upward: ▫️ Revenue: $60–62B ▫️ Adj. EPS: $21.75–$23.00 🔬 Positive developments in the pipeline (Orforglipron, Jaypirca, Kisunla) present very strong catalysts that will support growth in the medium to long term. 💼 It also appears to be continuing its focus on innovation with the acquisitions of SiteOne and Verve Therapeutics and the Purdue collaboration. 📈 Comment: Eli Lilly is demonstrating not only strong sales growth but also a structural transformation. Supported by its leadership in the GLP-1 class, cardiometabolic protection data, and R&D investments, the pipeline offers a defensive and growth combination for long-term investors. #LLY #EliLilly #Balance Sheet #GLP1 #Zepbound #Mounjaro #HealthcareSector #StockAnalysis

🧠 $BMNR | The art of Ethereum accumulation, or a strategy lesson? 🔹 July 29: 625K $ETH purchased, avg: $3,755 🔹 August 4: Position increased to 833K ETH, avg cost $3,492 🔹 Was the new 208K ETH purchased at an average price of $2,702? ❗️Yet, spot ETH never fell below $3,380 during this period. ➡️So how did BMNR buy at such a low price? Answer: Could be forward agreements or structured derivatives contracts. ETH was around $2,500 during the "big bang" announcement at the end of June. Call rights were likely created at that time and are now being activated. This may be the reason for the recent surge in the stock: Investors are waking up to this strategic buying. If ETH additions continue at this rate, BMNR will be one of the few companies collecting below the spot price. Tommy L and his team may be making a very smart play. #ETH #Ethereum #BMNR #CryptoStocks #Blockchain #InvestmentStrategy #SmartMoney

📉 Unfortunately, a lackluster earnings report for AMD. I was afraid of weak EPS, and it came true. At least there are positive signals on the forward guidance side. However, when expectations are set high, high price volatility is inevitable. If we hold above $170, perhaps even close the week above this level, we will have survived with minimal damage. The market loves to exaggerate. Conversely, if a correction is possible, a dip to $140-$150 could be a buying opportunity for those looking to add to their portfolio. 📢 Here are my key points: • Q3 guidance does not include the MI308 revenues planned for sale to China. The sale is still awaiting approval. However, there is a large amount of equipment in stock, ready for immediate shipment. • We still haven't seen the expected AI boom. Lisa Su points to the MI350 ramp-up for this. The market and investors now want to see results. The second half of 2025 is critical.

Some of the strongest cardano cnts plays imho (not financial advice) are $IAG - decentralized digital storage and compute making amazing headway with Fortune 50 companies. $FLDT. FluidTokens is not just a lending platform but also working to bring Bitcoin to cardano. $TITAN - an aggregator of various decentralized physical infrastructures networks (DePin) and mining investor that brings value to holders. $BANK which brings DeFi and mining shares to holders. And there are a few others I'd like to expand to but can't at the moment like $AGIX which is a promising AI venture. $GENS has been slower to develop than I'd like but it could end up being a strong choice for Bitcoin DeFi and RWAs. Always do your own research. Diversification is key without becoming spread too thin. What is the utility of the project? Is the team visibly building and what value do they bring to holders? Have your key holdings that you continually stack and set yourself some targets.